In yesterday’s Wall Street session, AVROBIO Inc. (NASDAQ:AVRO) shares traded at $1.26, down -3.82% from the previous session.
As of this writing, 8 analysts cover AVROBIO Inc. (NASDAQ:AVRO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $4.00. Given the previous closing price of $1.31, this indicates a potential upside of 205.34 percent. AVRO stock price is now 36.74% away from the 50-day moving average and 37.12% away from the 200-day moving average. The market capitalization of the company currently stands at $60.15M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $3.64 as their price target over the next twelve months.
.
Insiders disposed of 245,123 shares of company stock worth roughly $0.31 million over the past 1 year. A total of 2.66% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AVRO stock. A new stake in AVROBIO Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $819,000. VIRTU FINANCIAL LLC invested $51,000 in shares of AVRO during the first quarter. In the first quarter, TANG CAPITAL MANAGEMENT LLC acquired a new stake in AVROBIO Inc. valued at approximately $47,000. FNY INVESTMENT ADVISERS, LLC acquired a new stake in AVRO for approximately $33,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in AVRO valued at around $31,000 in the second quarter. In total, there are 65 active investors with 56.00% ownership of the company’s stock.
Wednesday morning saw AVROBIO Inc. (NASDAQ: AVRO) opened at $1.2880. During the past 12 months, AVROBIO Inc. has had a low of $0.56 and a high of $1.93. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for AVRO is $0.9230 and a two-hundred day moving average price translates $0.9201 for the stock.
The latest earnings results from AVROBIO Inc. (NASDAQ: AVRO) was released for Mar, 2023.
AVROBIO Inc.(AVRO) Company Profile
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
